We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings to Delta4 a deep financial expertise from his 20 years with banks in Austria and Switzerland, and as a CFO and Business Angel Investor working with start-ups and young businesses.
We are looking forward to Alfred joining, now that Delta4 gains ever more exposure to commercial partners in the global pharmaceutical and life science industry. He will have a critical role in further developing our processes and in supporting the future growth of Delta4.
With the financing round that we successfully closed earlier this year, Delta4 is now in the position to further accelerate the pace of its development. This is the right time for me to step down as Delta4‘s interim Chief Financial Officer and to hand over the responsibilities of this role to Alfred. I feel privileged to have been able to contribute to the early stage of Delta4’s growth, which managed to ready two promising drug programs for clinical development within the last year and is now turning into an organization with several exciting live drug development projects running in parallel, for which the results will be available early next year.
Following Alfred’s arrival I will resume my position as a member of the Company’s Advisory Council, and am looking forward to supporting the continuing development of the company from that position.